Ultromics
Oxford
About Ultromics
Ultromics develops AI-powered software solutions to assist in cardiovascular disease diagnosis through echocardiography. The company provides platforms that support clinicians in interpreting echocardiogram data by applying machine learning to detect patterns and abnormalities that may indicate heart conditions. Ultromics offers its flagship product, EchoGo, which automates the analysis of echocardiograms and delivers quantitative reports on cardiac function and structure. The software integrates with existing clinical workflows and is designed to enhance decision-making consistency while reducing variability in scan interpretation. Ultromics focuses on leveraging data-driven approaches to support early detection of conditions such as heart failure and coronary artery disease. Its technology is built on research collaborations and large-scale clinical datasets, aiming to improve diagnostic outcomes and support clinical efficiency.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $113.8M
- Last round: Series Unknown (Dec 2025)
- Website: ultromics.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Health Care, Health Diagnostics, Medical, Software
Social Profiles
Canonical: https://fsome.com/organization/ultromics-101943 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.